Associated Papers
Functional annotation of the Hippo pathway somatic mutations in human cancers.
Han H et al.
Nature Communications, 2024
39572544 (PubMed )
Supplement: 41467_2024_54480_MOESM3_ESM.zip › Supplementary_Data › Supplementary_Data_3.xlsx › All_Hippo_missense_mutations
Re-evaluation of missense variant classifications in NF2.
Sadler KV et al.
Human Mutation, 2022
35332608 (PubMed )
Supplement: HUMU-43-643-s001.xlsx › Sheet1
Molecular alterations of the NF2 gene in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Zhang N et al.
Oncology Reports, 2017
The myosin phosphatase targeting protein (MYPT) family: a regulated mechanism for achieving substrate specificity of the catalytic subunit of protein phosphatase type 1δ.
Grassie ME et al.
Archives of Biochemistry and Biophysics, 2011
Functional inactivation of NF2/merlin in human mesothelioma.
Thurneysen C et al.
Lung Cancer (amsterdam, Netherlands), 2009
Self-masking in an intact ERM-merlin protein: an active role for the central alpha-helical domain.
Li Q et al.
Journal of Molecular Biology, 2007
Mutational spectrum of the NF2 gene: a meta-analysis of 12 years of research and diagnostic laboratory findings.
Ahronowitz I et al.
Human Mutation, 2007
Tumorigenic transformation by CPI-17 through inhibition of a merlin phosphatase.
Jin H et al.
Nature, 2006
Structural basis for neurofibromatosis type 2. Crystal structure of the merlin FERM domain.
Shimizu T et al.
The Journal of Biological Chemistry, 2002
Screening for mutations in the neurofibromatosis type 2 (NF2) gene in sporadic meningiomas.
De Vitis LR et al.
Human Genetics, 1996
Select a paper to view details